The medical community is demonstrating considerable interest in Asenlix, a recently developed therapy designed to address the symptoms of depression. Unlike traditional antidepressants that primarily work on serotonin, Asenlix offers a novel mechanism of action, seemingly impacting several neurotransmitter pathways involved in mental balance. Early